← Back to Search

Other

INV-202 for Metabolic Syndrome

Phase 1
Waitlist Available
Research Sponsored by Inversago Pharma Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days

Summary

This trial is testing a new drug called INV-202 to see if it is safe and effective for people with metabolic syndrome. The study will look at how the drug is processed in the body and its effects on conditions like high blood sugar and large waist size over a few weeks.

Eligible Conditions
  • Metabolic Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number and Frequency of Adverse Events
Secondary study objectives
Pharmacokinetic profile of INV-202

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: INV-202Experimental Treatment1 Intervention
INV-202 25mg by mouth once daily
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo by mouth once daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
INV-202
2022
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

Inversago Pharma Inc.Lead Sponsor
3 Previous Clinical Trials
523 Total Patients Enrolled
1 Trials studying Metabolic Syndrome
243 Patients Enrolled for Metabolic Syndrome
Glenn D Crater, MDStudy DirectorInversago Pharma
1 Previous Clinical Trials
40 Total Patients Enrolled
~10 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top